RE:RE:3 months of consolidation. Longest plateau over the last 5yA 3rd scenario and my preferred, good news like 3 for 3 non-recurence at six month and the stock spikes north of $X, all warrants and options are exercised bringing in $19 million. Uplist to the NASDAQ with a public offering, no warrants, bringing in another $30 million. TLT is fully funded for couple of years.
realistically, if the brain cancer will be activated via low dose radiation then I really don't see significant cost to TLT of the trial.
OPK can fund Ph2 NMIBC as part of a distribution/marketing deal.
jojomarch wrote: There is clearly two trains of thoughts in regards to the inflow of capital ; the PP camp and the JV camp . My personal analysis tells me our clinical results are unique and deserve a financing at a higher valuation . In the last PP , RW could of made it bigger but he made it small so that the next round would be at higher levels . TLT will get a bigger market cap with a JV/licensing not with a PP . An outsider/big pharma with deep pockets will peg the SP of TLT not the venture market makers/destroyers .The deal i'm predicting will happen before Ph 2b starts .
GLTA